Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations

Immunopharmacology and Immunotoxicology

Volumn 37, Issue 1, 2015, Pages 103-109

  D'Ambrosio, Daniele ^a   Steinmann, Jörg ^b   Brossard, Patrick ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cell migration; Immune response; Lymphocyte subsets; Lymphocyte trafficking; Sphingosine 1 phosphate receptor

Indexed keywords

CD16 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD45RO ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; L SELECTIN; PLACEBO; PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; THIAZOLE DERIVATIVE;

ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; HEART RATE; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY T LYMPHOCYTE; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL COUNT; NORMAL HUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE SUBPOPULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOLOGY;

ANTIGENS, CD20; ANTIGENS, CD3; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HEALTHY VOLUNTEERS; HUMANS; LYMPHOCYTE COUNT; MALE; RECEPTORS, IGG; RECEPTORS, LYSOSPHINGOLIPID; T-LYMPHOCYTE SUBSETS; THIAZOLES;

EID: 84918767094     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2014.993084     Document Type: Article

References (23)

1. Bolli MH, Abele S, Binkert C, et al. 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 2010;53:4198-4211.
2. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 2012;30:69-94.
3. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-360.
4. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115:84-105.
5. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
6. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-852.
7. Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 2011;69:408-413.
8. Brossard P, Derendorf H, Xu J, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 2013;76:888-896.
9. Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2011; 337:547-556.
10. Olsson T, Boster A, Fernández O, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 2014;85:1198-1208.
11. Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet 2014;384:2036-2045.
12. R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: http://www.R-project.org/ [last accessed 6 Oct 2014].
13. Bohler T, Waiser J, Schutz M, et al. Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. Int J Clin Pharmacol Ther 2003;41:482-487.
14. von Budingen HC, Bar-Or A, Zamvil SS. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 2011;23: 713-720.
15. Bohler T, Waiser J, Schuetz M, et al. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol Dial Transplant 2004;19:702-713.
16. Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007;8:1337-1344.
17. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-1267.
18. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010;75:403-410.
19. Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J 2002;16:1874-1878.
20. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
21. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
22. Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol 2005;175:7973-7980.
23. Serpero LD, Filaci G, Parodi A, et al. Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol 2013;8:1106-1113.